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Stage at diagnosis of breast cancer in sub-Saharan Africa: 
a systematic review and meta-analysis
Elima Jedy-Agba, Valerie McCormack, Clement Adebamowo, Isabel dos-Santos-Silva
Summary
Background The incidence of breast cancer in sub-Saharan Africa is relatively low, but as survival from the disease in the 
region is poor, mortality rates are as high as in high-income countries. Stage at diagnosis is a major contributing factor 
to poor survival from breast cancer. We aimed to do a systematic review and meta-analysis on stage at diagnosis of breast 
cancer in sub-Saharan Africa to examine trends over time, and investigate sources of variations across the region.
Methods We searched MEDLINE, Embase, Web of Knowledge, and Africa-Wide Information to identify studies on 
breast cancer stage at diagnosis in sub-Saharan African women published before Jan 1, 2014, and in any language. 
Random-eﬀ ects meta-analyses were done to investigate between-study heterogeneity in percentage of late-stage breast 
cancer (stage III/IV), and meta-regression analyses to identify potential sources of variation. Percentages of women 
with late-stage breast cancer at diagnosis in sub-Saharan Africa were compared with similar estimates for black and 
white women in the USA from the Surveillance, Epidemiology, and End Results database.
Findings 83 studies were included, which consisted of 26 788 women from 17 sub-Saharan African countries. There 
was wide between-study heterogeneity in the percentage of late-stage disease at diagnosis (median 74∙7%, 
range 30∙3–100%, I²=93∙3%, p<0∙0001). The percentage of patients with late-stage disease at diagnosis did not vary 
by region in black women, but was lower in non-black women from southern Africa than in black women in any 
region (absolute diﬀ erence [AD] from black women in western Africa [reference group] –18·1%, 95% CI –28·2 to –8·0), 
and higher for populations from mixed (urban and rural) settings rather than urban settings (13∙2%, 5∙7 to 20∙7, in 
analyses restricted to black women). The percentage of patients with late-stage disease at diagnosis in black Africans 
decreased over time (–10∙5%, –19∙3 to –1∙6; for 2000 or later vs 1980 or before), but it was still higher around 2010 
than it was in white and black women in the USA 40 years previously.
Interpretation Strategies for early diagnosis of breast cancer should be regarded as a major priority by cancer control 
programmes in sub-Saharan Africa.
Funding None.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
The incidence of breast cancer is highest in high-
income countries (HICs), but has been rising in 
low-income and middle-income countries (LMICs).1,2 
Survival rates for breast cancer are poorer in LMICs 
than in HICs and most deaths from breast cancer now 
occur in less developed parts of the world. In 2012, 
about 53% of all newly diagnosed cases of breast cancer, 
and about 58% of deaths, occurred in LMICs.3 Breast 
cancer incidence in LMICs is likely to increase further 
in forthcoming decades as a result of population ageing 
and increased adoption of the lifestyles of HICs.1,2
Breast cancer incidence in sub-Saharan Africa is among 
the lowest in the world. Estimated age-standardised 
rates in 2012 ranged from 27 cases per 100 000 women in 
middle Africa to 39 cases per 100 000 women in 
southern African regions. However, mortality due to 
cancer is as high as in high-incidence countries; estimated 
age-standardised rates in 2012 ranged from 15 deaths per 
100 000 women in middle Africa to 20 deaths per 
100 000 women in western Africa.3 These rates are higher 
than that of North America for the same year 
(age-standardised rate 14·8 cases per 100 000 women), 
which has a higher breast cancer incidence (age-
standardised rate 91·6 cases per 100 000 women).3
Stage at diagnosis is a major determinant of survival 
from breast cancer; early-stage disease is associated with a 
better prognosis than late-stage disease,4 a pattern present 
in sub-Saharan Africa.5–8 Earlier stage at diagnosis, 
combined with therapeutic advances, was a major 
contributor to the sharp reductions in breast cancer 
mortality rates in the past two decades in most HICs.4 
By contrast, most patients with breast cancer in 
sub-Saharan Africa present with late-stage disease, thought 
to be due to poor awareness, an absence of organised early 
detection programmes, and poor facilities for accurate and 
timely diagnosis and treatment.5,9–17 Variations in stage of 
breast cancer at diagnosis across sub-Saharan Africa and 
over time in some countries in sub-Saharan Africa have 
been previously reported in individual settings,5,7,9,13,18,19 but 
have not, to our knowledge, been examined systematically 
across sub-Saharan Africa.
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In this study, we aimed to systematically review the 
published literature on stage at diagnosis of breast 
cancer in sub-Saharan Africa, examine trends over 
time, and investigate possible sources of between-study 
heterogeneity, which might help to identify appropriate 
approaches for stage-migration of this disease in 
the region.
Methods
Search strategy and selection criteria
For this systematic review and meta-analysis, we developed 
a study protocol (appendix p 1) based on the PRISMA 
guidelines (appendix p 4). We searched four databases 
(MEDLINE, Embase, Web of Knowledge, and Africa-Wide 
Information) to identify all studies published before 
Jan 1, 2014, which reported on stage at diagnosis of 
primary invasive breast cancer in women in sub-
Saharan Africa. The UN classiﬁ cation20 was used to deﬁ ne 
sub-Saharan African countries and to group them 
according to region (ie, southern, eastern, western, and 
middle Africa). We did an initial keyword search and 
subsequent searches based on Medical Subject 
Headings (MeSH) with various combinations of search 
terms “breast cancer*”, “breast neoplasm*”, “breast 
carcinoma*”, “breast sarcoma*”, “breast tumor*”, “breast 
tumour*”, or “breast malignanc*”, AND “stage”, 
“presentation”, “grade”, “clinical features”, or “clinical 
ﬁ ndings”, AND “Africa” (appendix p 7). No restrictions 
were imposed on the ethnicity or race of women, whether 
diagnoses were done in public or private settings, age at 
diagnosis, or language of the publication.
We identiﬁ ed and reviewed articles in a two-step process. 
The ﬁ rst step consisted of a title and abstract review to 
identify records that were deemed potentially eligible for 
inclusion. This review was done by one of three authors 
(EJ-A, Id-S-S, or VM) to exclude publications that were 
duplicates; that were from north Africa (ie, Algeria, Egypt, 
Libya, Morocco, Sudan, Tunisia, and Western Sahara20); 
that did not focus on breast cancer (eg, studies of “all 
cancers”); that did not include women with breast cancer 
(eg, surveys on awareness); that did not provide 
information on stage (eg, pathology series, papers about 
screening); or that focused exclusively on breast cancer in 
men. Articles that restricted inclusion to a particular stage 
(eg, metastatic breast cancer) were also excluded. Reviews 
and conference proceedings were not included, but their 
references were cross-checked for completeness. Studies 
that included both female and male patients with breast 
cancer were included, even if they did not provide enough 
information to allow the exclusion of male patients, 
because men typically represented less than 2% of all 
study participants. A random sample of 50% of the total 
abstracts was independently reviewed by one of the other 
two authors, which showed no disagreements on which 
papers to select for full-text review.
Quality assessment and data extraction
In the second step, all full-text articles retrieved were 
reviewed to conﬁ rm eligibility and, if eligible, data were 
extracted. EJ-A assessed all articles for eligibility and 
extracted the data, using an adapted version of a pre-tested 
data entry electronic form.21 All articles were independently 
reviewed by one of the other two reviewers (Id-S-S or VM). 
Data were extracted from each eligible paper on the 
numbers of patients who presented in stages I, II, III, and 
IV at diagnosis, or at early (I/II) and late (III/IV) stages if 
Research in context
Evidence before this study
We preliminarily searched MEDLINE with the terms “Breast 
Cancer” OR “Breast Carcinoma” AND “Stage” AND “Diagnosis” 
or “presentation” AND “Africa” OR “Sub-Saharan Africa”. No 
language restrictions were used. Previous studies have reported 
a wide variation in stage at diagnosis of breast cancer across 
sub-Saharan Africa, but none has examined trends in stage at 
diagnosis over time or investigated potential sources of 
variations across the region.
Added value of this study
We provide the most comprehensive synthesis to date of the 
available evidence on stage at diagnosis of breast cancer in 
sub-Saharan Africa. This review showed that most patients 
in sub-Saharan Africa were diagnosed at a late 
stage (stages III/IV). There was, however, a wide range of 
estimates across the region; the reasons for which were 
unclear. The percentage of women with late-stage disease at 
diagnosis was, as expected, higher in black women than 
non-black women; however, no clear diﬀ erences exist in 
black women by region or type of health facility, except that 
the percentage was lower in urban settings than in rural or 
urban areas. This review also highlights the paucity of 
published data on breast cancer stage from certain parts of the 
region (eg, from middle Africa).
Implications of all the available evidence
Although some improvements in stage at diagnosis of breast 
cancer in sub-Saharan Africa have occurred over the past few 
decades, very advanced disease is still prevalent at diagnosis in 
many settings. Nevertheless, within the region, public-sector 
settings exist with a much improved stage proﬁ le, indicating that 
stage migration is achievable in such settings—ie, in the absence 
of organised screening. To prevent avoidable deaths from this 
potentially good-prognosis cancer, breast cancer control 
measures require a strong emphasis on early diagnosis and 
treatment. Earlier diagnosis is dependent on the time window in 
which the patient has symptomatic disease; thus eﬀ orts to 
promote early presentation and faster referrals, diagnosis, and 
treatment need strengthening. 
For more on Africa-Wide 
Information see https://www.
ebscohost.com/academic/africa-
wide-information
See Online for appendix
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only this combined information was provided; country; 
study design; study population and type of clinical setting 
(eg, primary, secondary, or tertiary clinical facility; 
population-based cancer registry; public, private, or mixed 
patients); year of diagnosis; race; average age at time of 
diagnosis (mean or median; if only age categories were 
reported the mean age was estimated from the mid-point 
and the reported numbers in each category); and methods 
and classiﬁ cation used to ascertain stage. Time at 
diagnosis in the original papers was either the time at 
clinical or pathological diagnosis.
If a study provided numbers for each speciﬁ c American 
Joint Committee Cancer Tumour Node Metastases (TNM) 
category (eg, T2, N0, M0; appendix p 14), we used these to 
derive numbers in each one of the four stages. Whenever 
available, we extracted data on menopausal status, tumour 
characteristics (eg, histology, size, grade, receptor status), 
and time from ﬁ rst symptoms to diagnosis. Disagreements 
between extractors were discussed and a consensus 
reached. Most papers with missing information were 
from studies done several decades ago, hence no attempt 
was made to contact their authors because it was unlikely 
that the required information could still be retrieved. 
If there were several papers for the same study period, 
setting, and author, the paper with the most information 
on tumour stage was selected for inclusion.
The quality of the papers included in the review was 
assessed independently by two reviewers. An adapted 
version of the standardised quality assessment criteria 
developed by Eng and colleagues21 was used to assess the 
potential for selection and information bias as well as the 
availability of data on key variables (eg, age at diagnosis 
and year of diagnosis, tumour grade; details in the 
appendix; p 9). A quality score ranging from 0–28 (low to 
high quality) was given to each paper.
Data analysis
The primary outcome was percentage (p34) of breast cancer 
diagnosed at late stages (stages III/IV), deﬁ ned as p34=n34/n, 
where n34 is the number of women who presented at 
stages III or IV and n is the number of women with known 
stage information. The suite of metan and metaprop 
commands from Stata (version 13) were used to graphically 
display population-speciﬁ c late-stage percentages and to 
estimate pooled percentages using random eﬀ ect 
models. The metaprop command was speciﬁ cally designed 
to model binary data, thereby allowing for proportions 
near boundaries (ie, in this instance near 100% late-stage 
cancer). Between-population heterogeneity was assessed 
using I² statistic and the p value for heterogeneity 
(Cochrane’s Q statistic). To examine potential sources 
of heterogeneity, population-speciﬁ c estimates were 
stratiﬁ ed by relevant clinicoepidemiological variables, 
and meta-regression analyses were done to identify 
independent correlates of percentage of late-stage disease. 
Study-level determinants of late-stage disease are expressed 
as absolute diﬀ erences (AD) in the percentage of patients 
with late-stage disease (p34). Analyses were ﬁ rst done in all 
study populations (black and non-black African) and then 
in black African populations only. The latter analyses 
excluded non-black African populations, which were from 
South Africa, because of their known privileged access to 
health care. The potential for small study bias was assessed 
using funnel plots and the Egger test.22
To compare late-stage breast cancer in sub-Saharan 
Africa with corresponding ﬁ gures for white women and 
black women in the USA, relevant data were extracted 
from the Surveillance, Epidemiology, and End Results 
(SEER) database, which includes information on all cases 
of invasive primary breast cancer in women from nine US 
population-based cancer registries23 for two time periods: 
1973–2002 and 1998–2011. The SEER database provided 
numbers of in-situ, localised, regional, and distant 
(metastatic) breast cancer cases as well as numbers with 
unknown or missing stage. There were no age restrictions. 
The SEER summary staging classiﬁ cation was used to 
estimate the percentage of patients with regional or 
distant disease (proxy for stages III/IV) out of all patients 
with breast cancers of known stage.
Figure 1: Study selection
322 records identiﬁed
 from Africa-Wide 
 Information
675 abstracts screened (after removing duplicates)
456 records identiﬁed 
 from Web of 
 Science
183 records identiﬁed 
 from MEDLINE
284 records identiﬁed 
 from Embase
505 excluded
 7 non-human studies 
 111 not done in sub-Saharan Africa 
 152 not breast cancer studies 
 21 not done in women 
 46 conference abstracts 
 133 no information on stage or stage not mentioned in abstract 
 35 no stage distribution, only a particular stage given 
170 full-text articles assessed for eligibility
23 additional papers identiﬁed 
 through references 
101 excluded 
 8 meeting abstracts or PhD theses
 76 no information on stage 
 7 study population overlapped with another study 
 9 stage distribution was assumed or not original 
 1 attempts to retrieve paper unsuccessful 
83 studies eligible and included
9 excluded 
 1 study population overlapped with another study
 1 stage distribution excluded stage 4 patients (operable breast 
  cancer only)
 1 stage distribution unknown
 6 attempts to retrieve paper or abstracts unsuccessful
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Role of the funding source
There was no funding source for this study. EJ-A, VM, 
and Id-S-S had full access to all the data in the study and 
EJ-A and Id-S-S had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Our search retrieved 675 articles, of which 170 were 
considered as potentially relevant (ﬁ gure 1). The full text 
was retrieved for all of these articles except for six, which 
could not be traced through institutional libraries or 
direct contact with the authors (attempts to contact 
authors proved futile). The sample sizes of two of the 
untraceable studies24,25 were 47 and 120 according to 
Edmund and colleagues.26
The full-text review identiﬁ ed 83 eligible papers from 
17 sub-Saharan African countries consisting of late-stage 
disease estimates for 91 distinct study populations; ﬁ ve 
studies provided separate estimates for diﬀ erent subsets of 
participants (ie, for pregnant or lactating and non-pregnant 
or non-lactating women27 or diﬀ erent racial groups12,28–30). 
For three studies,31–33 we obtained estimates that diﬀ ered 
from those published because T3N1M0 tumours in the 
original articles were classiﬁ ed as stage II, but they should 
be stage III according to the 7th edition of the American 
Joint Committee on Cancer Breast Cancer Staging 
Manual.34 Four studies35–38 provided information on the 
tumour (T1–4) only and, for these, T3/T4 was regarded as a 
proxy for stages III/IV. The characteristics of the included 
studies are summarised in table 1; study-speciﬁ c details 
and references are given in the appendix (p 14). They 
comprised 26 788 patients with breast cancer, with sample 
sizes ranging from 12 to 2346 (median 141; appendix p 14). 
Stage information was available for 24 213 (90·4%) patients. 
36 studies (43%) were from Nigeria (8407 patients with 
cancer staging) and 16 studies (19%) were from 
South Africa (10 182 patients with cancer staging). 
35 studies (42%) were consecutive case series and the 
remaining were convenience case series (ie, patients seen 
in pathology or radiotherapy departments only or studies 
in which not all eligible patients who reported at the 
surgery or oncology clinics were included; table 1). The 
average age at diagnosis was less than 45 years in 34% of 
studies, between 45–49 years in 43% of studies, and 
50 years or older in 19% of studies. Age was not reported in 
only three studies (4%; table 1). The mean year of diagnosis 
ranged from 1960 to 2011, and was 2000 or later for 40% of 
the studies.
There was wide variation in the distribution of stage at 
diagnosis in sub-Saharan Africa. For example, in studies 
that provided stage IV-speciﬁ c estimates, the percentage of 
women diagnosed with stage IV breast cancer ranged from 
4%56 to 70%27 (ﬁ gure 2). Consequently, between-population 
heterogeneity was wide (I²=93·3%; p<0·0001) in the 
percentage of late-stage cancers (III/IV) (median 74·7%; 
range 30·3–100), with 59 (65%) of study populations 
yielding an estimate of greater than 70% (ﬁ gure 3).
Nine studies from western and eastern Africa were done 
exclusively in black women.5,37,38,42–47 The remaining 
58 studies did not report on race, but their populations 
were assumed to have the racial composition of their 
countries’ population and, hence, to consist pre dominantly 
(≥80%) of black women. Studies from South Africa 
included exclusively39–41 or predominantly (≥80%) black 
women;18 or predominantly (≥80%) non-black women (ie, 
white, Indian, or coloured women14,36,50–53); or provided 
separate estimates for black women and non-black 
women12,28–30 (appendix p 14).
Black women from South Africa presented much later 
than their non-black counterparts, but with marked 
Studies Study populations Patients with 
breast cancer
Patients with known 
breast cancer, n (%)
Total 83 91 26 788 24 213 (90·4%)
Race
Black† 75 76 18 805 16 669 (88·6%)
Non-black‡ 8 15 7983 7544 (94·5%)
Region or country
Western Africa 48 49
Nigeria 36 37 8623 8407 (97·5%)
Benin 2 2 204 204 (100%)
Ghana 5 5 1969 1191 (60·5%)
Mali 2 2 324 324 (100%)
Other§ 3 3 797 719 (90·2%)
Eastern or middle Africa 19 19
Tanzania 5 5 1310 1151 (87·7%)
Kenya 2 2 287 157 (54·7%)
Ethiopia 3 3 1267 841 (66·4%)
Madagascar 2 2 289 233 (80·6%)
Uganda 3 3 562 502 (89·3%)
Other¶ 4 4 445 302 (67·9%)
Southern Africa 16 23
South Africa 16 23 10 711 10 182 (95·1%)
Study design
Convenience case series 48 55 10 780 9788 (90·8%)
Consecutive case series 35 36 16 008 14 425 (90·1%)
Study population
Urban 27 34 15 571 14 208 (91·2%)
Mixed (rural and urban) 56 57 11 217 10 005 (89·2%)
Type of health facility
Tertiary, secondary, or 
primary||
9 12 1639 1503 (91·7%)
Tertiary 72 77 24 742 22 399 (90·5%)
Not reported in original 
study
2 2 407 311 (76·4%)
Age at diagnosis (years)**
<45 years 28 29 5475 4840 (88·4%)
≥45 to <50 years 36 37 7882 7218 (91·6%)
≥50 years 16 22 11 056 9841 (89·0%)
Not reported in original 
study
3 3 2375 2314 (97·4%)
(Table 1 continues on next page)
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between-population heterogeneity within each racial 
group (I²>97% for both groups; ﬁ gure 4). Four South 
African studies examined racial diﬀ erences (appendix 
p 11), which consistently showed a higher percentage of 
late-stage cancer in black Africans (range 74–91%) than 
white Africans (30–44%); the percentages of late-stage 
cancer in Indian and coloured women were intermediate, 
even when all the participants were diagnosed at the 
same health facility. However, these results were not 
adjusted for socioeconomic status because of a scarcity of 
information from the original publications.
Fully-adjusted meta-regression analysis (adjusting for 
region or race, study design, setting, facility type, age, 
and year of diagnosis) conﬁ rmed the diﬀ erence between 
racial groups; the percentage of late-stage cancers was 
18·1% lower (95% CI –28·2 to –8·0) for non-black women 
from South Africa than for black women in western Africa. 
By contrast, analysis restricted to black Africans revealed 
no diﬀ erence in late-stage cancer diagnosis between the 
three sub-Saharan African regions (table 2).
After adjustment for region or race, no diﬀ erences in 
late-stage disease were observed between consecutive or 
convenience case series, or by type of health facility 
(table 2). Studies done in mixed urban or rural populations 
had a higher percentage of women with late-stage disease 
than those done in urban populations, and this ﬁ nding 
remained signiﬁ cant in the fully adjusted model 
(AD 12·9%, 95% CI 5·5 to 20·3) and in the analysis 
restricted to black Africans (AD 13·2%, 5·7 to 20·7; 
table 2).
A smaller percentage of women aged 50 years or older 
had late-stage disease than those younger than 45 years 
(AD –13·2%, 95% CI –21·2 to –5·3), but most studies of 
older women consisted predominantly of non-black 
South Africans. Consequently, the age diﬀ erence 
attenuated markedly on adjustment for region and race, 
and disappeared in analyses restricted to black Africans 
(table 2). A slight improvement in stage at diagnosis was 
observed over time (appendix p 12). In the fully-adjusted 
meta-regression model, the percentage of women with 
late-stage disease was lower in black Africans diagnosed 
since 2000 compared with women diagnosed before 1980 
(AD –10·5%, 95% CI –19·3 to –1·6; table 2). In analyses 
restricted to black Africans, the percentage of women 
with late-stage cancer was lower in studies that did not 
report year of diagnosis than studies published 
before 1980, but this ﬁ nding was not statistically 
signiﬁ cant (table 2). Because the years of publication of 
these studies ranged from 2002 to 2011, it is likely that 
patients recruited into these studies would have been 
diagnosed in recent years.
The TNM or the Manchester staging classiﬁ cation 
(appendix p 14) were used in most studies, but this 
information was missing in 21 studies (table 1). No clear 
diﬀ erences in the percentage of late-stage disease were 
observed between studies that reported the staging 
classiﬁ cation used and studies that did not, or between 
studies done in facilities where there was access to imaging 
methods (eg, radiographs)—either routinely or in clinically 
suspicious cases—and studies done in settings without 
imaging facilities (table 2).
Few studies reported on tumour characteristics or 
duration of symptoms (appendix p 21). In studies of 
black African populations that reported on these 
characteristics, late-stage disease at diagnosis was 
positively associated with mean tumour size (Pearson 
correlation coeﬃ  cient r=0·63, p=0·004, based on data 
Studies Study populations Patients with 
breast cancer
Patients with known 
breast cancer stage, n (%)
(Continued from previous page)
Year of diagnosis††
Before 1980 11 16 3971 3782 (95·2%)
1980–1999 32 34 11 125 10 737 (96·5%)
2000 or after 33 33 8648 6733 (77·8%)
Not reported in original 
study
7 8 3044 2961 (97·3%)
Staging methods
Clinical and imaging 25 26 10 416 9516 (91·4%)
Clinical only 10 10 975 967 (99·2%)
Not reported in original 
study
48 55 15 397 13 730 (89·2%)
Staging classiﬁ cation
TNM 50 57 20 388 18 048 (88·5%)
Manchester 11 11 1436 1426 (99·3%)
Not reported in original 
study
22 23 4964 4739 (95·5%)
Study quality scores‡‡
≥23 (highest quality) 12 12 4067 3569 (87·8%)
22–20 26 27 6181 5721 (92·6%)
19–17 31 38 14 541 13 327 (91·7%)
<17 (lowest quality) 14 14 1999 1596 (79·8%)
Data are n or n (%). TNM=Tumour, Lymph Node, and Metastasis staging system. *Five studies provided separate estimates 
for diﬀ erent subsets of participants (ie, for pregnant or lactating and non-pregnant or non-lactating women27 or diﬀ erent 
ethnic groups12,28–30). †Includes seven southern African studies12,28–30,39–41 that reported estimates for black women only; 
one southern African study18 that presented only an overall (all ethnic groups combined) estimate, but reported that 
>80% of their study population was black; nine studies5,37,38,42–47 from western and eastern Africa that were done exclusively 
in black women, as well as the remaining 58 studies from these two regions that did not report on race, but were assumed 
to have been done in predominantly black women (ie, >80% black; see appendix p 14), which corresponded to 76 study 
population groups because one Nigerian study27 presented separate estimates for pregnant or lactating and non-pregnant 
or non-lactating women (appendix p 14). ‡Includes 15 southern African study population groups: four studies14,48–50 that 
did not report on race but were assumed to be predominantly non-black, four studies36,51–53 that present only overall 
estimates but reported an ethnically mixed population with ≤80% being black, and four multi-ethnic studies12,28–30 that 
together reported separate estimates for seven non-black population groups (appendix p 14). §Includes one study from 
Guinea (178 cases, 124 cases with known stage), one from Niger (146 cases, 146 cases with known stage), and one from 
Senegal (473 cases, 449 cases with known stage). ¶Includes one study from Rwanda (145 cases, seven cases with known 
stage), one from Zimbabwe (84 cases, 79 cases with known stage), one from Eritrea (82 cases, 82 cases with known 
stage), and one from Democratic Republic of the Congo (formerly known as Zaire; 134 cases, 134 cases with known stage). 
||All studies that recruited participants from secondary and primary health centres also included a tertiary centre. **Mean 
or median age at breast cancer diagnosis. If only age categories were reported, mean or median age was estimated from 
the mid-point and the reported number in each age category. The three studies in which age was not reported in the 
original category did not provide suﬃ  cient information to allow their allocation into one of the three age categories: 
Ajekigbe54 reported that 50·8% of the participants were aged <50 years; Amir and colleagues55 reported that 90% of the 
participants were aged <50 years; and Pegoraro and colleagues36 reported that 50% were between aged 45–64 years 
(appendix p 14). ††Middle year of the time interval during which patients were recruited. ‡‡Categories represent quartiles 
of the overall score distribution (appendix p 9).
Table 1: Study characteristics
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from 19 studies), but not with self-reported mean 
duration of symptoms (r=–0·14, p=0·42, 35 studies) or 
with percentages of tumours classiﬁ ed as invasive ductal 
carcinomas (r=0·09, p=0·50, 53 studies), oestrogen-
receptor positive (r=–0·03, p=0·91, 15 studies), or grade 3 
(r=0·21, p=0·26, 32 studies; appendix p 21).
The median study quality score was 19·5 
(IQR 17·5–21·5), with no evidence of regional or racial 
diﬀ erences. No variation in the percentage of women 
diagnosed with late-stage breast cancer was observed by 
study quality (table 2). The funnel plot (appendix p 13) 
and the value of the Egger’s test for small study bias 
(p=0·01) were diﬃ  cult to interpret because of the marked 
between-population heterogeneity.
The proportion of women with late-stage breast cancer 
at diagnosis declined markedly in the USA between 
1973 and 2011: from 50% to 27% in white women, and 
from 60% to 32% in black women23 (ﬁ gure 5). By contrast, 
most study-speciﬁ c estimates of late-stage disease in 
black sub-Saharan African women remained well above 
60% from the 1970s to 2011, albeit with some indication 
of a slight downward trend in some settings (ﬁ gure 5). 
Notably, the proportion of late-stage disease in black 
women in sub-Saharan Africa in the most recent study 
years (around 2010) was still higher than in black women 
from the USA 40 years previously. The proportion of 
women with late-stage disease in southern Africa 
remained unchanged for non-black Africans, but seemed 
to decline somewhat in black Africans. Remarkably, only 
two studies were done after 2000 in the southern African 
region. Both studies were done in South Africa: one in 
non-black Africans14 and one in black Africans.18 By 
contrast, the number of studies from eastern and 
western Africa published after 2000 was higher than in 
previous decades, although most had relatively small 
sample sizes.
Discussion
To our knowledge, this is the ﬁ rst systematic review of 
stage at diagnosis of breast cancer in sub-Saharan Africa. 
We compiled data from 83 studies consisting of 
24 213 patients with staged cancers. The ﬁ ndings 
highlight two main issues. First, our ﬁ ndings show the 
paucity of data on one of the most important clinical 
Figure 2: Study-speciﬁ c breast cancer stage at diagnosis
Study-speciﬁ c distribution of stages I, II, III, and IV cancers. Percentage of T3/T4 cancers was used as a proxy for percentage of stage III/IV cancers in four studies.35–38 Percentage with metastases (M1) 
was given in three studies24,35,37 and was used as percentage of stage IV. Race as deﬁ ned in table 1 and in the appendix (p 14). Study-speciﬁ c references given in the appendix (p 14). B=black. C=coloured. 
I=Indian. NPL=non-pregnant or non-lactating women. PL=pregnant or lactating women. W=white.
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Figure 3: Study-speciﬁ c 
breast cancer stage at 
diagnosis
Study-speciﬁ c percentage of 
late-stage disease (III/IV) 
ranked by increasing 
magnitude. Percentage of 
T3/T4 cancers was used as a 
proxy for percentage of 
stage III/IV cancers in four 
studies.35–38 Race as deﬁ ned in 
table 1 and in the appendix 
(p 14). Study-speciﬁ c 
references given in the 
appendix (p 14). B=black. 
C=coloured. DRC=Democratic 
Republic of the Congo. 
I=Indian. NPL=non-pregnant 
or non-lactating women. 
PL=pregnant or lactating 
women. W=white.
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Figure 4: Study-speciﬁ c 
percentage of late-stage 
breast cancer at diagnosis, by 
region of sub-Saharan Africa
B=black African. C=coloured. 
I=Indian. NPL=non-pregnant 
or non-lactating women. 
PL=pregnant or lactating 
women. W=white. Study-
speciﬁ c references given in the 
appendix (p 14). *Weights are 
from random eﬀ ects analyses.
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prognostic markers of breast cancer in this region. 
Speciﬁ cally, no published data from middle Africa were 
identiﬁ ed, and data from southern Africa were 
restricted to one country (South Africa), with only two 
studies done after 2000 (one in black Africans and 
another in non-black Africans). Furthermore, no study 
presented data from population-based cancer registries. 
Second, the ﬁ ndings show that most patients in 
sub-Saharan Africa (77% across all black study 
populations) were diagnosed at stages III/IV. Although 
this overall situation might seem grave, the presence 
of public-sector sub-Saharan Africa settings with 
improved stage proﬁ le needs to be highlighted because 
those settings reveal that progress in stage migration of 
breast cancer can be made within the public sector 
setting in which mammography is often unavailable. 
However, the reasons for the marked heterogeneity 
between populations, which is present even in analyses 
restricted to black Africans, are not entirely clear—no 
distinct patterns deﬁ ne the better settings. Late-stage 
breast cancer was, as expected, more frequent in 
black Africans than in non-black Africans; however, no 
clear diﬀ erences in the percentage of late-stage cancers 
at diagnosis by region or type of health facility were 
observed in black African women, except that the 
percentage of late-stage cancers at diagnosis was lower 
in urban settings. There was evidence of stage 
migration of breast cancer over time in black Africans 
diagnosed after 2000, consistent with the downward 
trend within studies in late-stage disease at diagnosis 
described by one of the studies in this review. 
McCormack and colleagues18 reported a decrease in the 
frequency of stage III/IV cancers in South Africa 
from 66% in 2006–07 to 46% in 2010–12.
We did not ﬁ nd a strong association between age at 
diagnosis and late-stage cancer at diagnosis in black 
African women. Most patients were aged 35–49 years at 
diagnosis (approximately 10–15 years younger than 
patients in developed countries).57 This ﬁ nding likely 
reﬂ ects the younger age structure of the sub-Saharan 
African population, consequent to higher fertility and 
shorter life expectancy, and the lower prevalence of 
risk factors in older generations than in young 
generations, rather than any inherent biological 
diﬀ erences in disease aggressiveness between black and 
white patients. Consistent with this interpretation is the 
fact that, at a study level, late-stage cancer at diagnosis 
was not correlated with tumour grade, which could 
indicate that late-stage cancer at diagnosis is not entirely 
a consequence of black African women having 
more biologically aggressive forms of disease—indeed 
a 2014 review21 suggests that oestrogen-receptor-
positive disease constitutes two-thirds of tumours in 
black women from sub-Saharan Africa. Late-stage disease 
was, however, positively correlated with mean tumour size 
(as expected given that tumour size is used to derive 
stage), consistent with delays in access to health care.
Increased breast cancer awareness and improvements 
in health care over time have been paralleled by decreases 
in tumour size and downstaging of breast cancer in other 
Figure 5: Trends in stage of breast cancer at diagnosis in sub-Saharan Africa in 1960–2011, and in the USA in 1973–2002 and 1988–2011
The US estimates represent percentage of patients with breast cancer with regional or distant disease (as a proxy for stages III/IV) out of all patients with known stage 
in the Surveillance Epidemiology End Results (SEER) database (see Methods); the SEER summary staging classiﬁ cation was used for both time periods: 1973–2002 
(based on 365 695 white women and 31 781 black women with breast cancer in the USA) and 1998–2011 (based on 780 137 white women and 96 526 black women 
with breast cancer in the USA). The discontinuity between the two time series was due to a change in staging classiﬁ cation. The sub-Saharan Africa estimates 
correspond to percentage of patients with stage III/IV breast cancer at diagnosis; the size of the point estimate symbols are proportional to the size of the study.
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LMICs.58,59 However, studies have reported low levels of 
breast cancer awareness in the general population and 
health-care professionals in sub-Saharan Africa.60,61 The 
poor awareness contributes to the high frequency of late-
stage cancer at diagnosis seen in sub-Saharan Africa.62,63 
Other barriers to access, such as distance to health-care 
facility, also play a role in this region.64
Most studies used the TNM or the Manchester staging 
classiﬁ cations, but only a quarter reported on the staging 
methods used. Of these, most studies relied on both 
clinical and imaging methods, but a few studies used 
clinical methods only. Although the clinical methods 
only approach leads to under-staging,65 most women in 
settings where imaging procedures are unavailable or 
unaﬀ ordable are likely to have presented at advanced 
stages when clinical methods might suﬃ  ce.66 This is 
consistent with our ﬁ nding of no diﬀ erences in late-stage 
disease depending on whether staging methods were 
reported and, if reported, by the type used.
There was no correlation, at a study level, between 
percentage of late-stage disease and average self-reported 
duration of symptoms (ie, time between onset of 
symptoms and diagnosis). The extent to which this 
ecological-level association reﬂ ects a similar absence of 
an association at an individual level is unclear. Women 
might not recognise symptoms because of poor breast 
cancer awareness,67,68 or they might not accurately 
remember the dates on which they ﬁ rst noticed 
symptoms. Nevertheless, the average duration of 
symptoms was between 8 months and 12 months in 
most studies (appendix p 21), indicating that for the most 
part advanced stage at diagnosis might be a result of 
delayed diagnosis. Hence, a large window exists in which 
delays to diagnosis can be shortened.
The frequency of late-stage disease at diagnosis in black 
women in sub-Saharan Africa was higher than in white 
and black women from the USA in 1970–2010, including 
during the pre-mammography screening era (screening 
in the USA began in 197669). This shows that, through 
more rapid diagnosis of palpable clinical disease, 
considerable improvements can be made before expensive 
systems for the detection of preclinical disease are 
warranted. In sub-Saharan Africa, where mammography 
is often unavailable or unaﬀ ordable, stage migration 
through breast cancer awareness and improved access to 
diagnostic facilities, not mammo graphic screening, is 
urgently required.
Major strengths of this review include the detailed and 
inclusive search strategy, which included non-English 
publications; the large sample size of more than 
24 000 women with breast cancer in the region; and the 
use of standard methods for study identiﬁ cation, and data 
extraction and synthesis. There were also limitations. The 
representativeness of the review might have been 
compromised by several factors. First, we included 
studies from only 17 of 49 sub-Saharan Africa countries, 
albeit together they represent 71% of the total population 
in the region, with most studies based on convenience 
samples of patients. Second, by deﬁ nition, the large 
numbers of patients with breast cancer in the region who 
never reach a health-care facility could not be included. 
Dickens and colleagues64 showed that distance to a tertiary 
care facility was a major determinant of access to 
diagnosis even within a relatively small geographical area 
(ie, Soweto in Johannesburg, South Africa). Because the 
patients included in this review are, by deﬁ nition, patients 
who were able to reach a health-care facility, predominantly 
tertiary centres, they might not be a representative sample 
of all patients with breast cancer in sub-Saharan Africa. 
Third, some participants might have been included in 
more than one study; to minimise this, whenever papers 
from the same institution and recruitment period were 
identiﬁ ed, we only included the paper that had the more 
comprehensive information on stage at diagnosis. Fourth, 
six potentially eligible papers could not be retrieved; the 
sample sizes for two of these papers are known to be 
small, and therefore their exclusion is not likely to have 
substantially aﬀ ected our ﬁ ndings. Finally, the absence of 
information on staging methods and procedures in many 
studies and the absence of standardisation in staging 
procedures between studies, and possibly even within 
studies, might have obscured some of the ﬁ ndings. 
Staging is aﬀ ected by neoadjuvant chemotherapy, but this 
treatment is not available in most sub-Saharan Africa 
settings.9 Neoadjuvant chemotherapy was mentioned in 
only two papers included in this review,14,70 and whether 
staging was ascertained before or after chemotherapy was 
not clear.
This review showed that the percentage of late-stage 
breast cancer at diagnosis in black populations from 
sub-Saharan Africa around 2010 was higher than in 
black and white populations in the USA 40 years 
previously. Cancer control strategies in the region 
should target early detection and diagnosis of 
symptomatic disease as one essential component of the 
strategy to improve survival from breast cancer. In most 
settings, symptom duration of 8–12 months shows that 
there is a considerable delay between symptom onset 
and diagnosis and thus a considerable time window 
exists in which to realistically achieve early detection 
and diagnosis. Population-level interventions for the 
stage migration of breast cancer have been shown to be 
successful in Tanzania71 and other LMICs, such as 
Malaysia.72 Several sub-Saharan Africa studies have 
shown improved survival rates in women diagnosed at 
earlier stages,6,19 which shows that early diagnosis 
coupled with timely and appropriate treatment can 
prevent deaths from this disease in this region.
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